Background: Patients are increasingly expected to take an active role in their own care. Participation in nursing documentation can support patients to take this active role since it provides opportunities to express care needs and preferences. Yet, patient participation in electronic nursing documentation is not self-evident.
Objective: To explore how home-care patients perceive their participation in electronic nursing documentation.
Methods: Semi-structured interviews were conducted with 21 home-care patients. Interview transcripts were analysed in an iterative process based on the principles of reflexive inductive thematic analysis.
Results: We identified a typology with four patient types: 'high need, high ability', 'high need, low ability', 'low need, high ability' and 'low need, low ability'. Several patients felt a need for participation because of their personal interest in health information. Others did not feel such a need since they trusted nurses to document the information that is important. Patients' ability to participate increased when they could read the documentation and when nurses helped them by talking about the documentation. Barriers to patients' ability to participate were having no electronic devices or lacking digital skills, a lack of support from nurses and the poor usability of electronic patient portals.
Conclusion: Patient participation in electronic nursing documentation varies between patients since home-care patients differ in their need and ability to participate. Nurses should tailor their encouragement of patient participation to individual patients' needs and abilities. Furthermore, they should be aware of their own role and help patients to participate in the documentation.
Patient Or Public Contribution: Home-care patients were involved in the interviews.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327866 | PMC |
http://dx.doi.org/10.1111/hex.13492 | DOI Listing |
Background: Patients with Alzheimer's disease (AD) often experience burdensome neuropsychiatric symptoms, including agitation which occurs in both home and long-term care (LTC) facilities, and is associated with substantial increases in caregiver burden and LTC placements. AXS-05 (45-mg dextromethorphan/105-mg bupropion), a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, approved by the FDA for major depressive disorder, is being investigated for treatment of AD agitation (ADA). AXS-05 has been evaluated in 2 randomized, double-blind studies: Phase 2 ADVANCE-1 (NCT03226522); Phase 3 ACCORD (NCT04797715).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Northumbria University, Newcastle, United Kingdom.
Background: Mealtimes are a fundamental part of life; eating and drinking well is vital for health well-being. People living with dementia are at increased risk of eating and drinking difficulties, and may experience difficulties at mealtimes due to the cognitive component of this condition. Such difficulties are prevalent in care homes, where people living with dementia are often dependent on carers at mealtimes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Camden and Islington NHS Foundation Trust, London, United Kingdom; University College London, London, United Kingdom.
Background: Long-term care (LTC) home residents may be isolated or lonely. Social connection is important for their physical, mental and cognitive health, quality of life and care. However, measuring social connection in LTC residents is challenging and there are no existing measures with adequately established psychometric properties.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Soleo Health, Frisco, TX, USA.
Background: The approval of anti-amyloid monoclonal antibodies (mAbs) provides a novel approach to the treatment of Alzheimer's disease. Infusions in alternative sites of care can benefit the patient financially and logistically, but coverage is largely payor dependent. The purpose of this study is to describe observations from this national complex specialty pharmacy around the safety of anti-amyloid mAb infusions in alternative sites of care, including the home.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurobehavioral Systems, Inc, Berkeley, CA, USA.
Background: Paper-and-pencil neuropsychological tests have traditionally been considered the "gold standard" for clinical testing in AD/ADRD, but they have significant limitations: They are time-consuming, costly to administer, vulnerable to examiner bias and error, and unavailable to some patients due to location, transportation challenges, and cost. Manual tests also fail to comprehensively analyze many aspects of test performance. Computerized neuropsychological test batteries have been developed to address these shortcomings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!